Drug Trial Radar · NCT02590432
An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation
Last checked: Nov 19, 2026Latest source record: Aug 22, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
828
Actual
Start
Nov 1, 2015
Primary completion
Feb 5, 2018
Study completion Feb 5, 2018
Sponsor
- Lead sponsor
- Forest LaboratoriesAbbVie (ABBV)
- Sponsor type
- Industry
- Collaborators
- Ironwood Pharmaceuticals, Inc.
- First posted
- Oct 29, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to assess the potential of LINZESS® (linaclotide) treatment to induce the development of anti-drug antibodies (ADAs). The secondary objectives are to provide additional evidence supporting the long-term safety and efficacy of linaclotide in adult irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) participants and to evaluate lower doses of linaclotide.
Conditions
- Irritable Bowel Syndrome With Constipation
- Chronic Idiopathic Constipation
Interventions
LinaclotideDrug
Linaclotide capsules, orally, once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Positive Treatment-Related Anti-Drug Antibodies (ADA) in SerumTime frame: Baseline (Day 1) up to 52 weeks or 8 months post last dose if ADA positive at Week 52 (approximately 84 weeks)
Locations
79 sites in 1 country. Site status is shown where the registry gives one.
Pinnacle Research Group, LLC
Anniston, Alabama
North Alabama Research Center, LLC
Athens, Alabama
Alliance Clinical Research
Childersburg, Alabama
G & L Research, LLC
Foley, Alabama
Radiant Research, Inc.
Chandler, Arizona
Radiant Research, Inc.
Scottsdale, Arizona
Clinical Research Institute of Arizona, LLC
Surprise, Arizona
Clinical Research Consortium
Tempe, Arizona
Desert Sun Clinical Research, LLC.
Tucson, Arizona
Preferred Research Partners, Inc.
Little Rock, Arkansas
Applied Research Center of Arkansas
Little Rock, Arkansas
Kindred Medical Institute for Clinical Trials, LLC
Corona, California
Global Clinical Trials LLC
Costa Mesa, California
Diagnamics Inc
Encinitas, California
MD Studies, Inc.
Fountain Valley, California
Research Center of Fresno, Inc.
Fresno, California
VVCRD Clinical Research
Garden Grove, California
Facey Medical Foundation
Mission Hills, California
Clinical Trials Research
Sacramento, California
Northern California Research
Sacramento, California
Artemis Institute for Clinical Research
San Diego, California
Precision Research Institute
San Diego, California
Empire Clinical Research
Upland, California
Lynn Institute of Denver
Denver, Colorado
ZASA Clinical Research
Boynton Beach, Florida
Meridien Research
Bradenton, Florida
Clinical Research of Brandon LLC
Brandon, Florida
Clinical Physiology Associates
Fort Myers, Florida
Direct Helpers Research Center
Hialeah, Florida
Eastern Research, Inc.
Hialeah, Florida
Center for Advanced Gastroenterology
Maitland, Florida
Florida Medical Center and Research, Inc.
Miami, Florida
Clinical Neuroscience Solutions, Inc
Orlando, Florida
Accord Clinical Research
Port Orange, Florida
Meridien Research
St. Petersburg, Florida
River Birch Research Alliance, LLC
Blue Ridge, Georgia
North Georgia Clinical Research
Woodstock, Georgia
Northwest Clinical Trials
Boise, Idaho
Rockford Gastroenterology Associates
Rockford, Illinois
Iowa Digestive Center, PC
Clive, Iowa
Showing 40 of 79 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.